Early clinical outcomes of hybrid brachytherapy for locally advanced cervical cancer: making adverse situations in a favorable scenario.
image-guided adaptive brachytherapy
interstitial brachytherapy
local control
locally advanced cervical cancer
vaginal morbidity
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
04
05
2022
accepted:
05
08
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
ppublish
Résumé
To investigate the feasibility and early clinical outcomes of combined intra-cavitary (IC) and interstitial (IS) image-guided adaptive brachytherapy (IGABT) as curative and definitive treatment of patients treated with chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Data from medical records of all consecutive patients with histologically proven cervical cancer (FIGO 2018 stage IB-IV), treated by brachytherapy after CCRT at our institution between 2017 and 2020 were reviewed. One hundred and forty-two patients with LACC FIGO 2018 stages (IB: 20.4%, II: 31.7%, III: 45.8%, IV: 2.1%) underwent brachytherapy at our institution, out of which 53.5% underwent combined brachytherapy technique (IC/IS). Median number of implanted catheters was 3 (range, 1-6 catheters). None of the 142 patients required invasive hemorrhage management. With a median follow-up of 21.6 (95% CI [confidence interval]: 19.1-23.5%) months, local relapse was observed in nine patients (6.3%), with four showing persistent and progressive disease. The estimated 2-year local and pelvic relapse-free survival were 92% (95% CI: 84-96%) and 90% (95% CI: 83-94%), respectively. The estimated 2-year disease-free survival for the entire population was 80% (95% CI: 71-87%). The 2-year overall survival (OS) rate for the entire population was 92% (95% CI: 84-96%). Acute toxicity G3 was reported in two (1.4%) patients. High-grade late toxicity (grade 3) was reported in 9 (6.3%) patients. Combined IC/IS brachytherapy for LACC allows for recommended doses to achieve local control even in large tumors after CCRT improving target volume coverage, with low rates of acute morbidity. Hybrid brachytherapy technique (IC/IS) is essential to have a favorable scenario at the time of brachytherapy to correctly treat locally advanced cervical cancer patients.
Identifiants
pubmed: 36199941
doi: 10.5114/jcb.2022.118831
pii: 47660
pmc: PMC9528831
doi:
Types de publication
Journal Article
Langues
eng
Pagination
321-331Informations de copyright
Copyright © 2022 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
J Clin Oncol. 1999 May;17(5):1339-48
pubmed: 10334517
Radiother Oncol. 2016 Jan;118(1):160-6
pubmed: 26780997
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1091-8
pubmed: 25303889
Acta Oncol. 2013 Oct;52(7):1510-9
pubmed: 23962242
Radiother Oncol. 2016 Sep;120(3):412-419
pubmed: 27396811
Gynecol Oncol. 2008 Jan;108(1):154-9
pubmed: 17945337
Front Pharmacol. 2019 Feb 01;10:65
pubmed: 30774597
Brachytherapy. 2015 Mar-Apr;14(2):260-6
pubmed: 25555313
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1396-403
pubmed: 19581056
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1572-9
pubmed: 20800373
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):375-89
pubmed: 7673025
Eur J Surg Oncol. 2007 May;33(4):498-503
pubmed: 17156969
Cancer Radiother. 2021 Jul;25(5):463-468
pubmed: 34023215
Gynecol Oncol. 2014 Nov;135(2):231-8
pubmed: 25172763
Radiother Oncol. 2006 Jan;78(1):67-77
pubmed: 16403584
Oncologist. 2010;15(4):405-15
pubmed: 20332143
Cancer Radiother. 2015 Dec;19(8):710-7
pubmed: 26508320
Eur Radiol. 2019 Jan;29(1):309-318
pubmed: 29943182
Radiother Oncol. 2007 May;83(2):148-55
pubmed: 17531904
Radiother Oncol. 2016 Sep;120(3):447-454
pubmed: 27157510
Lancet Oncol. 2021 Apr;22(4):538-547
pubmed: 33794207
Radiother Oncol. 2019 Dec;141:123-129
pubmed: 31495516
Gynecol Oncol. 2009 Sep;114(3):404-9
pubmed: 19555996
Brachytherapy. 2021 Jul-Aug;20(4):748-754
pubmed: 33883092
Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):969-78
pubmed: 9276361
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Acta Oncol. 2015;54(9):1558-66
pubmed: 26406152
Radiother Oncol. 2016 Sep;120(3):480-485
pubmed: 27267048
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Gynecol Oncol. 2021 Feb;160(2):375-378
pubmed: 33293047
N Engl J Med. 1999 Apr 15;340(15):1137-43
pubmed: 10202164
Gynecol Oncol. 2020 Feb;156(2):328-334
pubmed: 31864683
Radiother Oncol. 2013 Apr;107(1):63-8
pubmed: 23452917
J Cancer. 2018 Jul 30;9(16):2938-2945
pubmed: 30123362
Gynecol Oncol. 2021 Apr;161(1):166-172
pubmed: 33563488
J Gynecol Oncol. 2014 Jul;25(3):206-13
pubmed: 25045433
Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):237-42
pubmed: 9054901
Ann Surg Oncol. 2014 May;21(5):1692-9
pubmed: 24407316
Am J Obstet Gynecol. 1979 Sep 15;135(2):181-4
pubmed: 474668
Gynecol Oncol. 2003 Jun;89(3):343-53
pubmed: 12798694
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):507-13
pubmed: 10661360